Cereno Scientific B CRNO B
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
The founder owns or has owned shares in this company within the past 6 months. See About.
A small speculative position may be justified after the Q2 report if clear operational progress is shown.
Clinical milestones and insider purchases are balanced against high dilution risk and short cash runway, warranting a neutral review.
Investors focus on clinical progress and insider purchases while dilution concerns remain.
NEUTRAL is the call. Neutral is the market mood. High risk means a lot can go wrong.
Latest change
- 27 Aug 2026 — Report shows continued zero revenue and widening loss driven by clinical activities plus sharply reduced cash after the quarter.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (13) — follow the company freeAbout the company
Cereno Scientific develops epigenetic HDAC inhibitors for cardiovascular and pulmonary diseases. The lead candidate CS1 is in phase IIb for pulmonary arterial hypertension (PAH). The company is in clinical development stage with no revenues.
Bull case
Activation of the first clinical site in the Phase IIb EPIMODE study and insider purchases provide operational momentum.
Bear case
High dilution risk from convertible financing and short cash runway limit upside.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| CS1 phase IIb data | Negative or delayed data → pipeline value declines and funding needs increase. | Positive data → re-rating toward higher multiples and partnership opportunities open. |
| Utilization of convertible facility | Heavy utilization → significant dilution and continued price pressure. | Limited utilization → better ownership structure and higher confidence. |
Why this signal
Clinical milestones and insider purchases are balanced against high dilution risk and short cash runway, warranting a neutral review.
Recent news
No new press releases or company-specific events have been published after 11 September 2026. The company participated in the H.C. Wainwright conference 14–16 September without new data. Topline results from the CS014 PK study are still expected in Q3 2026 and the first site in EPIMODE has been activated.